Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy AC Immune stock
Learn how to easily invest in AC Immune stock.
AC Immune SA is a biotechnology business based in the US. AC Immune shares (ACIU) are listed on the NASDAQ and all prices are listed in US Dollars. AC Immune employs 125 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in AC Immune
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ACIU – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
AC Immune stock price (NASDAQ: ACIU)Use our graph to track the performance of ACIU stocks over time.
AC Immune shares at a glance
|Latest market close||$4.82|
|52-week range||$4.68 - $12.50|
|50-day moving average||$5.50|
|200-day moving average||$6.59|
|Wall St. target price||$14.46|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.07|
Buy AC Immune shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy AC Immune stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
AC Immune price performance over time
|1 week (2022-01-11)||-1.83%|
|1 month (2021-12-17)||-3.98%|
|3 months (2021-10-18)||-19.53%|
|6 months (2021-07-16)||-34.78%|
|1 year (2021-01-15)||-18.72%|
|2 years (2020-01-17)||-47.61%|
|3 years (2019-01-18)||11.34|
|5 years (2017-01-18)||12.98|
AC Immune financials
|Gross profit TTM||$-44,056,000|
|Return on assets TTM||-20.37%|
|Return on equity TTM||-34.53%|
|Market capitalisation||$355.3 million|
TTM: trailing 12 months
AC Immune share dividends
We're not expecting AC Immune to pay a dividend over the next 12 months.
AC Immune share price volatility
Over the last 12 months, AC Immune's shares have ranged in value from as little as $4.68 up to $12.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AC Immune's is 0.817. This would suggest that AC Immune's shares are less volatile than average (for this exchange).
AC Immune overview
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.
AC Immune in the news
Supreme Court vaccine mandate ruling won't bar companies from demanding Covid shots for workers — Biden vows to advocate for that
Two of Sen. Kyrsten Sinema's former aides have lobbied for corporate giants looking to influence Joe Biden's agenda
Joe Manchin's former aides gain influential lobbying clients as their ex-boss battles Biden's agenda
Frequently asked questionsWhat percentage of AC Immune is owned by insiders or institutions?
Currently 60.543% of AC Immune shares are held by insiders and 28.397% by institutions. How many people work for AC Immune?
Latest data suggests 125 work at AC Immune. When does the fiscal year end for AC Immune?
AC Immune's fiscal year ends in December. Where is AC Immune based?
AC Immune's address is: Building B, Lausanne, Switzerland, 1015 What is AC Immune's ISIN number?
AC Immune's international securities identification number is: CH0329023102 What is AC Immune's CUSIP number?
AC Immune's Committee on Uniform Securities Identification Procedures number is: H00263105
More guides on Finder
Monie savings review
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Is Berkshire Hathaway the next $1 trillion stock?
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Tesla roars into 2022 after December drop
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
How to buy Austin Gold (AUST) stock when it goes public
Everything we know about the Austin Gold IPO, plus information on how to buy in.
How to buy VinFast stock when it goes public
Everything we know about the VinFast IPO, plus information on how to buy in.
NFT-funded LinksDAO moves $10.5 million closer to buying a golf course
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.
How to buy Nexalin Technology (NXL) stock when it goes public
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.
How to buy Specialty Building Products (SBP) stock when it goes public
Everything we know about the Specialty Building Products IPO, plus information on how to buy in.
Ask an Expert